Patents by Inventor Amir P. Tamiz
Amir P. Tamiz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11155603Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: GrantFiled: August 10, 2020Date of Patent: October 26, 2021Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz
-
Publication number: 20200362017Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: ApplicationFiled: August 10, 2020Publication date: November 19, 2020Inventors: ALEKSANDER S. POPEL, ELENA V. ROSCA, JACOB E. KOSKIMAKI, CORBAN G. RIVERA, NIRANJAN B. PANDEY, AMIR P. TAMIZ
-
Patent number: 10774131Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: GrantFiled: September 14, 2018Date of Patent: September 15, 2020Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz
-
Publication number: 20190002531Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumori-genic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: ApplicationFiled: September 14, 2018Publication date: January 3, 2019Inventors: ALEKSANDER S. POPEL, ELENA V. ROSCA, JACOB E. KOSKIMAKI, CORBAN G. RIVERA, NIRANJAN B. PANDEY, AMIR P. TAMIZ
-
Patent number: 10106597Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: GrantFiled: December 30, 2016Date of Patent: October 23, 2018Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz
-
Publication number: 20170174749Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: ApplicationFiled: December 30, 2016Publication date: June 22, 2017Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: ALEKSANDER S. POPEL, ELENA V. ROSCA, JACOB E. KOSKIMAKI, CORBAN G. RIVERA, NIRANJAN B. PANDEY, AMIR P. TAMIZ
-
Publication number: 20150307592Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer sonogram models and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: ApplicationFiled: May 11, 2015Publication date: October 29, 2015Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: ALEKSANDER S. POPEL, ELENA V. ROSCA, JACOB E. KOSKIMAKI, CORBAN G. RIVERA, NIRANJAN B. PANDEY, AMIR P. TAMIZ
-
Patent number: 9056923Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: GrantFiled: December 12, 2011Date of Patent: June 16, 2015Assignee: THE JOHNS HOPKINS UNIVERSITYInventors: Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz
-
Publication number: 20130316950Abstract: Mimetic peptides having anti-angiogenic and anti-tumorigenic properties and methods of their use for treating cancer, ocular diseases, such as age-related macular degeneration, and other-angiogenesis-dependent diseases are disclosed. More particularly, active non-cysteine analogs (mimetics), which exhibit anti-angiogenic activity in endothelial cell proliferation, migration, adhesion, and tube formation assays, anti-migratory activity in human breast cancer cells in vitro, anti-angiogenic and anti-tumorigenic activity in vivo in breast cancer xenograft models, and age-related macular degeneration models are disclosed. The presently disclosed mimetic peptides also exhibit anti-lymphangiogenic and directly anti-tumorigenic properties.Type: ApplicationFiled: December 12, 2011Publication date: November 28, 2013Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: Aleksander S. Popel, Elena V. Rosca, Jacob E. Koskimaki, Corban G. Rivera, Niranjan B. Pandey, Amir P. Tamiz
-
Patent number: 7262211Abstract: Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have at a group having a guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.Type: GrantFiled: December 4, 2002Date of Patent: August 28, 2007Assignee: Dendreon CorporationInventors: Amir P. Tamiz, L. Josue Alfaro-Lopez, Odile Esther Levy, Joseph Edward Semple
-
Patent number: 7019019Abstract: The present invention provides matriptase inhibitors and compositions thereof useful for treating cancer. Martripase is a trypsin-like serine protease active in the development of cancerous conditions, such as tumors and metastasis of cancer.Type: GrantFiled: December 18, 2003Date of Patent: March 28, 2006Assignee: Dendreon CorporationInventors: David F. Duncan, L. Josue Alfaro-Lopez, Mallareddy Komandla, Odile Esther Levy, Ofir Moreno, Joseph E. Semple, Amir P. Tamiz
-
Publication number: 20040186060Abstract: The present invention provides matriptase inhibitors and compositions thereof useful for treating cancer. Martripase is a trypsin-like serine protease active in the development of cancerous conditions, such as tumors and metastasis of cancer.Type: ApplicationFiled: December 18, 2003Publication date: September 23, 2004Applicant: Dendreon CorporationInventors: David F. Duncan, L. Josue Alfaro-Lopez, Mallareddy Komandla, Odile Esther Levy, Ofir Moreno, Joseph E. Semple, Amir P. Tamiz
-
Publication number: 20030207842Abstract: Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have at a group having a guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.Type: ApplicationFiled: December 4, 2002Publication date: November 6, 2003Inventors: Amir P. Tamiz, L. Josue Alfaro-Lopez, Odile Esther Levy, Joseph Edward Semple
-
Patent number: 6605621Abstract: The invention provides compounds of formula(I): X—L—X1 (I) wherein X, L, and X1 have any of the meanings defined in the specification; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson's disease, depression, or a disease wherein the administration of cocaine is indicated, comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.Type: GrantFiled: July 30, 2002Date of Patent: August 12, 2003Assignee: Georgetown UniversityInventors: Alan P. Kozikowski, Gian Luca Araldi, Amir P. Tamiz
-
Publication number: 20030144289Abstract: The invention provides compounds of formula (I):Type: ApplicationFiled: July 30, 2002Publication date: July 31, 2003Inventors: Alan P. Kozikowski, Gian Luca Araldi, Amir P. Tamiz
-
Patent number: 6586405Abstract: Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have P1 a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.Type: GrantFiled: December 7, 2000Date of Patent: July 1, 2003Assignee: Corvas International, Inc.Inventors: Joseph Edward Semple, Michael I. Weinhouse, Odile Esther Levy, Edwin L. Madison, Amir P. Tamiz
-
Patent number: 6440996Abstract: The invention provides compounds of formula (I): X—L—X1 (I) wherein X and X1 are substituted piperidine, cyclohexane, or tetrahydropyran rings, and L is a linking group between X and X1; as well a pharmaceutical composition comprising a compound of formula I; intermediates and methods useful for preparing a compound of formula I; and therapeutic methods for treating drug addiction, Parkinson's disease, depression, or a disease wherein the administration of cocaine is indicated, comprising administering a compound of formula I or a pharmaceutically acceptable salt thereof to a mammal in need of such treatment.Type: GrantFiled: October 7, 1999Date of Patent: August 27, 2002Assignee: Georgetown UniversityInventors: Alan P. Kozikowski, Gian Luca Araldi, Amir P. Tamiz
-
Publication number: 20020037857Abstract: Novel compounds having activity as non-covalent inhibitors of urokinase and having activity in reducing or inhibiting blood vessel formation are provided. These compounds have Pi a group having an amidino or guanidino moiety or derivative thereof. These compounds are useful in vitro for monitoring plasminogen activator levels and in vivo in treatment of conditions which are ameliorated by inhibition of or decreased activity of urokinase and in treating pathologic conditions wherein blood vessel formation is related to a pathologic condition.Type: ApplicationFiled: December 7, 2000Publication date: March 28, 2002Applicant: Corvas International, Inc.Inventors: Joseph Edward Semple, Michael I. Weinhouse, Odile Esther Levy, Edwin L. Madison, Amir P. Tamiz